NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) [Seeking Alpha]
NervGen Pharma Corp. - Common stock (NGEN)
Company Research
Source: Seeking Alpha
NGEN's regulatory engagement is strong, with expedited FDA pathways under discussion and a Phase 3 trial for up to 150 patients set to begin this summer. Recent $10M private investment and prior ATM sales provide near-term funding, but additional capital will be required before 2027 data readout. Leadership consolidation and Nasdaq focus signal operational maturity, while the NGEN pipeline remains tightly centered on NVG-291's pivotal trial. andresr/E+ via Getty Images Thesis NervGen Pharma Corp. ( NGEN ) is a biotech company that is still in the clinical stage and is working on treatments to repair nerve damage. When I last wrote about the stock, I called it This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NGEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no
Show less
Read more
Impact Snapshot
Event Time:
NGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGEN alerts
High impacting NervGen Pharma Corp. - Common stock news events
Weekly update
A roundup of the hottest topics
NGEN
News
- NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma Announces Voluntary Delisting from TSX Venture ExchangeGlobeNewswire
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsGlobeNewswire
- NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma to Participate at Upcoming Investor ConferencesGlobeNewswire
NGEN
Sec Filings
- 3/13/26 - Form 6-K
- 2/13/26 - Form 6-K
- 2/10/26 - Form 6-K
- NGEN's page on the SEC website